A systematic review and meta-analysis by Liyun et al. found an increased risk of gallbladder and biliary diseases with GLP-1 RAs, particularly at higher doses, longer durations, and for weight loss [5,6]. Since higher doses are often prescribed for weight loss rather than type 2 diabetes as in our case, the risk may vary with dosage [5]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.